JPWO2022193499A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022193499A5 JPWO2022193499A5 JP2023557092A JP2023557092A JPWO2022193499A5 JP WO2022193499 A5 JPWO2022193499 A5 JP WO2022193499A5 JP 2023557092 A JP2023557092 A JP 2023557092A JP 2023557092 A JP2023557092 A JP 2023557092A JP WO2022193499 A5 JPWO2022193499 A5 JP WO2022193499A5
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- acceptable salt
- ceutically acceptable
- optionally substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 60
- 150000001875 compounds Chemical class 0.000 claims 56
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims 7
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- -1 CF 3 Chemical group 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010066946 Craniofacial dysostosis Diseases 0.000 claims 1
- 201000006526 Crouzon syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019842 Hepatomegaly Diseases 0.000 claims 1
- 102000002227 Interferon Type I Human genes 0.000 claims 1
- 108010014726 Interferon Type I Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010053869 POEMS syndrome Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004431 deuterium atom Chemical group 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021081177 | 2021-03-16 | ||
| CNPCT/CN2021/081177 | 2021-03-16 | ||
| PCT/CN2021/106028 WO2022193499A1 (en) | 2021-03-16 | 2021-07-13 | Amino heteroaryl compounds and compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024510274A JP2024510274A (ja) | 2024-03-06 |
| JPWO2022193499A5 true JPWO2022193499A5 (https=) | 2024-07-23 |
| JP2024510274A5 JP2024510274A5 (https=) | 2024-07-23 |
Family
ID=83321944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557092A Pending JP2024510274A (ja) | 2021-03-16 | 2021-07-13 | アミノヘテロアリール化合物および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240246944A1 (https=) |
| EP (1) | EP4308556A4 (https=) |
| JP (1) | JP2024510274A (https=) |
| CN (1) | CN117083268B (https=) |
| CA (1) | CA3213816A1 (https=) |
| WO (1) | WO2022193499A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022135430A1 (en) | 2020-12-22 | 2022-06-30 | InventisBio Co., Ltd. | Heteroaryl compounds, preparation methods and uses thereof |
| TW202233600A (zh) * | 2021-02-06 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途 |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| WO2024044486A1 (en) * | 2022-08-22 | 2024-02-29 | Ajax Therapeutics, Inc. | Jak2 inhibitor compounds |
| US20260098017A1 (en) * | 2022-12-24 | 2026-04-09 | Tianjin Pharmaceutical Biotechnology Co., Ltd. | Novel aromatic ring derivative containing amide substitution and use thereof |
| WO2024174229A1 (en) * | 2023-02-24 | 2024-08-29 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Covalent binding compounds and compositions |
| CN116162093B (zh) * | 2023-04-25 | 2023-06-23 | 中南大学湘雅医院 | 一种tyk2抑制剂化合物及其用途 |
| CN117624126B (zh) * | 2023-12-05 | 2026-01-30 | 中国药科大学 | 选择性酪氨酸激酶2(tyk2)抑制剂化合物、合成方法及用途 |
| WO2025186427A1 (en) | 2024-03-08 | 2025-09-12 | Curia Spain, S.A.U. | Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib |
| WO2025255092A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a chromene derivative tcr inhibitor and a tyk2 inhibitor |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY194668A (en) | 2012-11-08 | 2022-12-12 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses |
| AR094537A1 (es) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| EP3080131B1 (en) | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| US10479793B2 (en) | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| ES2902995T3 (es) | 2016-10-07 | 2022-03-30 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| EP3848370B1 (en) | 2016-10-14 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| EP3541817B1 (en) | 2016-11-17 | 2020-12-23 | Bristol-Myers Squibb Company | Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha |
| CN110267964B (zh) | 2016-12-13 | 2022-05-03 | 百时美施贵宝公司 | 作为IL-12、IL-23及/或IFNα响应调节剂的经取代的杂芳基氧化膦化合物 |
| KR102717819B1 (ko) | 2017-07-28 | 2024-10-14 | 다케다 야쿠힌 고교 가부시키가이샤 | Tyk2 억제제 및 이의 용도 |
| MX2020005210A (es) | 2017-11-21 | 2020-08-20 | Bristol Myers Squibb Co | Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona. |
| EP3768667B1 (en) | 2018-03-22 | 2023-04-12 | Bristol-Myers Squibb Company | Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses |
| JP7179161B2 (ja) | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| JP7619951B2 (ja) | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| AU2019364336B2 (en) | 2018-10-22 | 2023-11-16 | Alumis Inc. | TYK2 inhibitors and uses thereof |
| CA3118094A1 (en) * | 2018-10-30 | 2020-05-07 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha |
| JP7530360B2 (ja) | 2018-11-30 | 2024-08-07 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| TWI800696B (zh) | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| CN111757878B (zh) | 2019-01-28 | 2023-07-28 | 江苏豪森药业集团有限公司 | 一种哒嗪类衍生物抑制剂、其制备方法和应用 |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| WO2020159904A1 (en) * | 2019-01-30 | 2020-08-06 | Bristol-Myers Squibb Company | Amide-disubstituted pyridine or pyridazine compounds |
| CN111909140A (zh) | 2019-04-12 | 2020-11-10 | 明慧医药（杭州）有限公司 | 作为tyk2抑制剂的杂环化合物及合成和使用方法 |
| JP2023523438A (ja) * | 2020-04-28 | 2023-06-05 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環式化合物 |
-
2021
- 2021-07-13 EP EP21931081.0A patent/EP4308556A4/en active Pending
- 2021-07-13 CA CA3213816A patent/CA3213816A1/en active Pending
- 2021-07-13 CN CN202180095847.0A patent/CN117083268B/zh active Active
- 2021-07-13 JP JP2023557092A patent/JP2024510274A/ja active Pending
- 2021-07-13 US US18/550,898 patent/US20240246944A1/en active Pending
- 2021-07-13 WO PCT/CN2021/106028 patent/WO2022193499A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022193499A5 (https=) | ||
| JP4713574B2 (ja) | ロスバスタチンアルキルエーテルを含まないロスバスタチンおよびその塩およびそれらを製造する方法 | |
| CA2436659A1 (en) | Cannabinoid receptor ligands | |
| HRP20090348T1 (hr) | Sulfoksimin-supstituirani pirimidini kao inhibitori cd i/ili vegf, njihova proizvodnja i primjena kao lijekova | |
| JP2020537657A5 (https=) | ||
| JP2022541467A (ja) | オーロラキナーゼ阻害剤およびその使用 | |
| RU2014106020A (ru) | Ингибиторы втк | |
| AR040803A1 (es) | Ligandos de receptores canabinoides, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o combinados, para la preparacion de medicamentos | |
| RU2005105683A (ru) | Обладающие ингибирующим действием на vegfr-2 и vegfr-3 антраниламидопиридины | |
| WO2018057973A4 (en) | Compounds and methods for ido and tdo modulation, and indications therefor | |
| JP2017501234A5 (https=) | ||
| JPWO2020112937A5 (https=) | ||
| RU99112569A (ru) | Бициклические арильные карбоксамиды и их терапевтическое применение | |
| KR840004119A (ko) | 항균제의 제조방법 | |
| JPS6097982A (ja) | セフエム誘導体、その製法および医薬組成物 | |
| US20230183188A1 (en) | Enpp1 modulators and uses thereof | |
| JPWO2001029035A1 (ja) | ２−ピリドン骨格を部分構造として有する４−オキソキノリジン抗菌剤 | |
| RU2007102576A (ru) | Новые индаэолкарбоксамиды и их применение | |
| JPWO2021071802A5 (https=) | ||
| WO2002062339A1 (en) | Antibacterial compounds | |
| JPH0615549B2 (ja) | セファロスポリン中間体の製法 | |
| KR930004263A (ko) | 피페리딘 유도체 화합물 | |
| JPH0246588B2 (https=) | ||
| JPWO2021071821A5 (https=) | ||
| JPS58213788A (ja) | β‐ラクタマーゼ阻害剤を有するアンピシリンおよびアモキシシリン誘導体 |